Innate Pharma S.A. ADS (IPHA) Stock Price

IPHAStock

$1.43−27.99%52W

Market Cap$159.73M

P/E—

PEG Ratio—

Div yield—

Beta0.96

IPHA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.28%

Price vs S&P 500 (4W)-15.00%

VGM Score42.32

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)18.20x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-61.69%

Cash Flow / Share (Quarterly)$-0.51

Price vs S&P 500 (YTD)-29.28%

Gross Margin (TTM)34.45%

Net Profit Margin (TTM)-804.07%

EPS (TTM)$-0.57

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$-0.57

Revenue Growth (5Y)-45.15%

EPS (Annual)$-0.62

ROI (Annual)-124.21%

Gross Margin (Annual)1.29%

Net Profit Margin (5Y Avg)-544.85%

Cash / Share (Quarterly)$0.13

Revenue Growth QoQ (YoY)86.42%

ROA (Last FY)-78.41%

Revenue Growth TTM (YoY)-1.63%

EBITD / Share (TTM)$-0.56

ROE (5Y Avg)-154.41%

Operating Margin (TTM)-806.37%

Cash Flow / Share (Annual)$-0.63

P/B Ratio28.10x

P/B Ratio (Quarterly)27.27x

Net Income / Employee (Annual)$-336,641

EV / Revenue (TTM)26.82x

Net Interest Coverage (TTM)0.39x

ROA (TTM)-97.40%

EV / EBITDA (TTM)15.12x

EPS Incl Extra (Annual)$-0.62

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)0.47x

3-Month Avg Trading Volume0.36M

52-Week Price Return-27.99%

Revenue / Employee (TTM)$40,410

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)51.86x

Asset Turnover (Annual)0.04x

52-Week High$2.62

Operating Margin (5Y Avg)-576.31%

EPS Excl Extra (Annual)$-0.62

CapEx CAGR (5Y)-58.48%

Tangible BV CAGR (5Y)-40.70%

26-Week Price Return-5.38%

Quick Ratio (Annual)1.14x

13-Week Price Return-13.32%

Total Debt / Equity (Annual)3.51x

Current Ratio (Quarterly)0.60x

Enterprise Value$177.68M

Revenue / Share Growth (5Y)-46.53%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-47.95%

Revenue / Employee (Annual)$19,083

Pretax Margin (Annual)-1764.51%

Cash / Share (Annual)$0.41

3-Month Return Std Dev68.17%

Gross Margin (5Y Avg)67.81%

Net Income / Employee (TTM)$-324,854

ROE (Last FY)-560.01%

Net Interest Coverage (Annual)-31.06x

EPS Basic Excl Extra (Annual)$-0.62

P/FCF (TTM)52.48x

Receivables Turnover (TTM)18.89x

Total Debt / Equity (Quarterly)5.25x

EPS Incl Extra (TTM)$-0.57

Receivables Turnover (Annual)5.35x

ROI (TTM)-127.92%

P/S Ratio (TTM)24.49x

Pretax Margin (5Y Avg)-532.69%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$0.12

Forward P/E33.00x

Price vs S&P 500 (52W)-43.52%

Year-to-Date Return-18.73%

5-Day Price Return1.56%

EPS Normalized (Annual)$-0.62

ROA (5Y Avg)-34.95%

Net Profit Margin (Annual)-1764.51%

Month-to-Date Return-7.13%

Cash Flow / Share (TTM)$-0.79

EBITD / Share (Annual)$-0.66

Operating Margin (Annual)-1937.85%

LT Debt / Equity (Annual)2.51x

ROI (5Y Avg)-49.81%

LT Debt / Equity (Quarterly)3.49x

EPS Basic Excl Extra (TTM)$-0.57

P/TBV (Quarterly)18.20x

P/B Ratio (Annual)18.20x

Pretax Margin (TTM)-804.07%

Book Value / Share (Annual)$0.12

Price vs S&P 500 (13W)-16.00%

Beta0.96x

P/FCF (Annual)0.72x

Revenue / Share (TTM)$0.07

ROE (TTM)-658.91%

52-Week Low$1.16

vGradeD

gGradeC

mGradeB

vgmGradeC

IPHA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IPHAInnate Pharma S.A. ADS	D	C	B	24.5x	-1.6%	34.5%	—	$1.43
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Innate Pharma S.A. ADS

Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ANKET platform and therapeutic antibodies to engage the innate immune system. The company generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Its pipeline includes lacutamab, monalizumab, and several other advanced immunotherapy candidates.